AstraZeneca jab is still in a clinical trial until February 2023

April 28th, 2021

Awake Goy

*** all the covid vaccine on the market are still on trial ***

Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults

ClinicalTrials.gov Identifier: NCT04516746

Recruitment Status : Active, not recruitingFirst Posted : August 18, 2020Last Update Posted : April 13, 2021

Sponsor:AstraZenecaCollaborator:Iqvia Pty LtdInformation provided by (Responsible Party):AstraZeneca

Study DescriptionGo to sections Brief Summary:The aim of the study is to assess the safety, efficacy, and immunogenicity of AZD1222 for the prevention of COVID-19.

Condition or disease	Intervention/treatment	Phase
COVID-19SARS-CoV-2	Biological: AZD1222Biological: Placebo	Phase 3

Detailed Description:The COVID-19 pandemic has caused major disruption to healthcare systems with significant socioeconomic impacts. Currently, there are no specific treatments available against COVID-19 and accelerated vaccine development is urgently needed. A safe and effective vaccine for COVID-19 prevention would have significant public health impact.Study DesignGo to sections

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	32459 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Intervention Model Description:	Participants are assigned to one of two or more groups in parallel for the duration of the study.
Masking:	Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:	Double Blind: two or more parties are unaware of the intervention assignment.
Primary Purpose:	Treatment
Official Title:	A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults, to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19
Actual Study Start Date :	August 28, 2020
Actual Primary Completion Date :	March 5, 2021
Estimated Study Completion Date :	February 14, 2023

Arms and InterventionsGo to sections

Arm	Intervention/treatment
Experimental: AZD1222Approximately 20,000 participants randomized to the AZD1222 arm	Biological: AZD1222AZD12222 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2-5 surface glycoprotein.
Placebo Comparator: PlaceboApproximately 10,000 participants randomized to the saline placebo arm	Biological: PlaceboCommercially available 0.9% (n/V) saline for injection.

Outcome MeasuresGo to sections
Primary Outcome Measures :

The efficacy of 2 IM doses of AZD1222 compared to saline placebo for the prevention of COVID-19 [ Time Frame: 1 year ]A binary response, whereby a participant is defined as a COVID-19 case if their first case of SARS-CoV-2 RT-PCR-positive symptomatic illness occurs≥ 15 days post second dose of study intervention. Otherwise, a participant is not defined as a COVID-19 case.
The safety and tolerability of 2 IM doses of AZD1222 compared to saline placebo [ Time Frame: a: 28 days post each dose of study Intervention. / b: from Day 1 post-treatment through Day 730. ]
1. Incidence of adverse events.
2. Incidence of serious adverse events, medically attended adverse events, and adverse events of special interest.
The reactogenicity of 2 IM doses of AZD1222 compared to saline placebo (Substudy only) [ Time Frame: 7 days post each dose of study intervention. ]Incidence of local and systemic solicited adverse events.

Secondary Outcome Measures :

The efficacy of 2 IM doses of AZD1222 compared tosaline placebo for the prevention of SARS-CoV-2 infection [ Time Frame: 1 year ]The incidence of the first post-treatment response (negative at baseline to positive post treatment with study intervention) for SARS-CoV-2 Nucleocapsid antibodies occurring greater than or equal to 15 days post second dose of study intervention.
The efficacy of 2 IM doses of AZD1222 compared to saline placebo for the prevention of symptomatic COVID-19 using CDC criteria [ Time Frame: 1 year ]The incidence of the first case of SARS-CoV-2 RT-PCR-positive symptomatic illness for a participant occurring at or after 15 days post second dose of study intervention using criteria from the CDC.
The efficacy of 2 IM doses of AZD1222 compared to saline placebo for the prevention of University of Oxford defined symptomatic COVID-19 [ Time Frame: 1 year ]The incidence of the first case of SARS-CoV-2 RT-PCR positive symptomatic illness occurring ≥ 15 days post second dose of study intervention using University of Oxford defined symptom criteria.
The efficacy of 2 IM doses of AZD12222 compared to saline placebo for the prevention of severe or critical symptomatic COVID-19. [ Time Frame: 1 year ]The incidence of SARS-CoV-RT-PCR-positive severe or critical symptomatic illness occurring 15 days or more post second dose of study intervention. The incidence of SARS-CoV-2 RT-PCR positive severe or critical symptomatic illness occurring post first dose of study intervention
The efficacy of 2 IM doses of AZD1222 compared to saline placebo for the prevention of COVID-19-related Emergency Department visits [ Time Frame: 1 year ]The incidence of COVID-19-related Emergency Department visits occurring ≥ 15 days post second dose of study intervention
Antibody responses to AZD1222 S antigen following 2 IM doses of AZD1222 or saline placebo (Substudy and Illness Visits only) [ Time Frame: 28 days post each dose ]Post-treatment GMTs and GMFRs in SARS-CoV-2 S, RBD antibodies (MSD serology assay); The proportion of participants who have a post-treatment seroresponse (≥ 4-fold rise in titers) to the S, RBD antigens of AZD1222 (MSD serology assay)
Anti-SARS-CoV-2 neutralizing antibody levels in serum following 2 IM doses of AZD1222 or saline placebo (Substudy and Illness Visits only) [ Time Frame: 28 days post each dose ]Post-treatment GMTs and GMFRs in SARS-CoV-2 neutralizing antibodies (wild-type assay or pseudo-neutralization assay); Proportion of participants who have a post-treatment seroresponse (≥ 4-fold rise in titers) to AZD1222 as measured by SARS-CoV-2 neutralizing antibodies (wild-type assay or pseudo-neutralization assay)
The efficacy of 2 IM doses of AZD1222 compared to saline placebo in the prevention of COVID-19 in all study participants, regardless of evidence of prior SARS-CoV-2 infection [ Time Frame: 1 year ]The incidence of the first case of SARS-CoV-2 RT-PCR-positive symptomatic illness occurring ≥ 15 days post second dose of study intervention regardless of evidence of prior SARS-CoV-2 infection
The efficacy of AZD1222 compared to saline placebo for the prevention of COVID-19 following the first dose [ Time Frame: 1 year ]The incidence of SARS-CoV-2 RT-PCR-positive symptomatic illness occurring post first dose of study intervention

https://clinicaltrials.gov/ct2/show/NCT04516746

Source

Jon Ossoff Victory Proves That the Israel Lobby Still Has an Iron Grip on Democrats

Italian police find ‘millions’ of vaccines in factory raid amid fears AstraZeneca jabs being hidden

AstraZeneca Changes Name Continues Use, Vaccine Lies & Only Thing Keeping Mask Illusion Going Is Us

Evidence suggests there was NEVER ANY DRUG TRIAL AT ALL for Pfizer’s COVID “vaccine” | FRAUD

Eight people to stand trial for role in 2016 Bastille Day attack

Do You Realize That The Government Is Still Paying Banks Not To Lend...?